{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,8]],"date-time":"2024-02-08T09:44:21Z","timestamp":1707385461358},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2023,6,12]],"date-time":"2023-06-12T00:00:00Z","timestamp":1686528000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,6,12]],"date-time":"2023-06-12T00:00:00Z","timestamp":1686528000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Urologie"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1007\/s00120-023-02121-5","type":"journal-article","created":{"date-parts":[[2023,6,12]],"date-time":"2023-06-12T09:02:23Z","timestamp":1686560543000},"page":"705-710","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Neue Antibiotika in der Behandlung von Harnwegsinfektionen","New antibiotics for the treatment of urinary tract infections"],"prefix":"10.1007","volume":"62","author":[{"given":"Florian M. E.","family":"Wagenlehner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,6,12]]},"reference":[{"key":"2121_CR1","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1186\/s13756-019-0656-6","volume":"8","author":"A Gomila","year":"2019","unstructured":"Gomila\u00a0A, Carratala\u00a0J, Eliakim-Raz\u00a0N, Shaw\u00a0E, Tebe\u00a0C, Wolkewitz\u00a0M et al (2019) Clinical outcomes of hospitalised patients with catheter-associated urinary tract infection in countries with a\u00a0high rate of multidrug-resistance: the COMBACTE-MAGNET RESCUING study. Antimicrob Resist Infect Control 8:198","journal-title":"Antimicrob Resist Infect Control"},{"issue":"5","key":"2121_CR2","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/nrmicro3432","volume":"13","author":"AL Flores-Mireles","year":"2015","unstructured":"Flores-Mireles\u00a0AL, Walker\u00a0JN, Caparon\u00a0M, Hultgren\u00a0SJ (2015) Urinary tract infections: epidemiology, mechanisms of infection and treatment options. Nat Rev Microbiol 13(5):269\u2013284","journal-title":"Nat Rev Microbiol"},{"issue":"8","key":"2121_CR3","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1007\/s00345-015-1722-1","volume":"34","author":"Z Tandogdu","year":"2016","unstructured":"Tandogdu\u00a0Z, Bartoletti\u00a0R, Cai\u00a0T, Cek\u00a0M, Grabe\u00a0M, Kulchavenya\u00a0E et\u00a0al (2016) Antimicrobial resistance in urosepsis: outcomes from the multinational, multicenter global prevalence of infections in urology (GPIU) study 2003\u20132013. World J Urol 34(8):1193\u20131200","journal-title":"World J Urol"},{"issue":"10325","key":"2121_CR4","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/S0140-6736(21)02724-0","volume":"399","author":"Antimicrobial Resistance Collaborators","year":"2022","unstructured":"Antimicrobial Resistance Collaborators (2022) Global burden of bacterial antimicrobial resistance in 2019: a\u00a0systematic analysis. Lancet 399(10325):629\u2013655","journal-title":"Lancet"},{"issue":"2","key":"2121_CR5","doi-asserted-by":"publisher","first-page":"153","DOI":"10.3184\/003685016X14616130512308","volume":"99","author":"CE Broughton","year":"2016","unstructured":"Broughton\u00a0CE, Van Den Berg\u00a0HA, Wemyss\u00a0AM, Roper\u00a0DI, Rodger\u00a0A (2016) Beyond the discovery void: new targets for antibacterial compounds. Sci Prog 99(2):153\u2013182","journal-title":"Sci Prog"},{"issue":"7309","key":"2121_CR6","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1038\/nature09197","volume":"466","author":"BD Bax","year":"2010","unstructured":"Bax\u00a0BD, Chan\u00a0PF, Eggleston\u00a0DS, Fosberry\u00a0A, Gentry\u00a0DR, Gorrec\u00a0F et\u00a0al (2010) Type IIA topoisomerase inhibition by a\u00a0new class of antibacterial agents. Nature 466(7309):935\u2013940","journal-title":"Nature"},{"issue":"3","key":"2121_CR7","doi-asserted-by":"publisher","first-page":"e0149221","DOI":"10.1128\/aac.01492-21","volume":"66","author":"NE Scangarella-Oman","year":"2022","unstructured":"Scangarella-Oman\u00a0NE, Hossain\u00a0M, Hoover\u00a0JL, Perry\u00a0CR, Tiffany\u00a0C, Barth\u00a0A et al (2022) Dose selection for phase\u00a0III clinical evaluation of gepotidacin (GSK2140944) in the treatment of uncomplicated urinary tract infections. Antimicrob Agents Chemother 66(3):e149221","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"2121_CR8","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1038\/s41585-020-0362-4","volume":"17","author":"FME Wagenlehner","year":"2020","unstructured":"Wagenlehner\u00a0FME, Bjerklund Johansen\u00a0TE, Cai\u00a0T, Koves\u00a0B, Kranz\u00a0J, Pilatz\u00a0A et\u00a0al (2020) Epidemiology, definition and treatment of complicated urinary tract infections. Nat Rev Urol 17(10):586\u2013600","journal-title":"Nat Rev Urol"},{"key":"2121_CR9","doi-asserted-by":"publisher","unstructured":"Evans S, Rubin DB, Powers JH, Follmann D (2018) Analysis populations in anti-infective clinical trials: whom to analyze? Stat Commun Infect Dis. 10(1):20170002. https:\/\/doi.org\/10.1515\/scid-2017-0002. Epub 2018 Aug 29. PMID: 30923606","DOI":"10.1515\/scid-2017-0002"},{"issue":"9981","key":"2121_CR10","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1016\/S0140-6736(14)62220-0","volume":"385","author":"FM Wagenlehner","year":"2015","unstructured":"Wagenlehner\u00a0FM, Umeh\u00a0O, Steenbergen\u00a0J, Yuan\u00a0G, Darouiche\u00a0RO (2015) Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a\u00a0randomised, double-blind, phase 3 trial (ASPECT-cUTI). Lancet 385(9981):1949\u20131956","journal-title":"Lancet"},{"issue":"6","key":"2121_CR11","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1093\/cid\/ciw378","volume":"63","author":"FM Wagenlehner","year":"2016","unstructured":"Wagenlehner\u00a0FM, Sobel\u00a0JD, Newell\u00a0P, Armstrong\u00a0J, Huang\u00a0X, Stone\u00a0GG et al (2016) Ceftazidime-avibactam versus doripenem for the treatment of complicated urinary tract infections, including acute pyelonephritis: RECAPTURE, a\u00a0phase\u00a03 randomized trial program. Clin Infect Dis 63(6):754\u2013762","journal-title":"Clin Infect Dis"},{"issue":"6","key":"2121_CR12","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/S1473-3099(16)30004-4","volume":"16","author":"Y Carmeli","year":"2016","unstructured":"Carmeli\u00a0Y, Armstrong\u00a0J, Laud\u00a0PJ, Newell\u00a0P, Stone\u00a0G, Wardman\u00a0A et al (2016) Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a\u00a0randomised, pathogen-directed, phase 3\u00a0study. Lancet Infect Dis 16(6):661\u2013673","journal-title":"Lancet Infect Dis"},{"issue":"13","key":"2121_CR13","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1001\/jama.2022.17034","volume":"328","author":"KS Kaye","year":"2022","unstructured":"Kaye\u00a0KS, Belley\u00a0A, Barth\u00a0P, Lahlou\u00a0O, Knechtle\u00a0P, Motta\u00a0P et\u00a0al (2022) Effect of cefepime\/enmetazobactam vs piperacillin\/tazobactam on clinical cure and microbiological eradication in patients with complicated urinary tract infection or acute Pyelonephritis: a randomized clinical trial. JAMA 328(13):1304\u20131314","journal-title":"JAMA"},{"issue":"12","key":"2121_CR14","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1016\/S1473-3099(18)30554-1","volume":"18","author":"S Portsmouth","year":"2018","unstructured":"Portsmouth\u00a0S, van Veenhuyzen\u00a0D, Echols\u00a0R, Machida\u00a0M, Ferreira\u00a0JCA, Ariyasu\u00a0M et al (2018) Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a\u00a0phase 2, randomised, double-blind, non-inferiority trial. Lancet Infect Dis 18(12):1319\u20131328","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"2121_CR15","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/S1473-3099(18)30722-9","volume":"19","author":"FME Wagenlehner","year":"2019","unstructured":"Wagenlehner\u00a0FME, Naber\u00a0KG (2019) Cefiderocol for treatment of complicated urinary tract infections. Lancet Infect Dis 19(1):22\u201323","journal-title":"Lancet Infect Dis"},{"issue":"14","key":"2121_CR16","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1056\/NEJMoa2105462","volume":"386","author":"PB Eckburg","year":"2022","unstructured":"Eckburg\u00a0PB, Muir\u00a0L, Critchley\u00a0IA, Walpole\u00a0S, Kwak\u00a0H, Phelan\u00a0AM et\u00a0al (2022) Oral tebipenem pivoxil hydrobromide in complicated urinary tract infection. N\u00a0Engl J Med 386(14):1327\u20131338","journal-title":"N Engl J Med"},{"issue":"9","key":"2121_CR17","doi-asserted-by":"publisher","first-page":"2616","DOI":"10.1093\/jac\/dkx139","volume":"72","author":"M Sims","year":"2017","unstructured":"Sims\u00a0M, Mariyanovski\u00a0V, McLeroth\u00a0P, Akers\u00a0W, Lee\u00a0YC, Brown\u00a0ML et al (2017) Prospective, randomized, double-blind, Phase\u00a02 dose-ranging study comparing efficacy and safety of imipenem\/cilastatin plus relebactam with imipenem\/cilastatin alone in patients with complicated urinary tract infections. J\u00a0Antimicrob Chemother 72(9):2616\u20132626","journal-title":"J Antimicrob Chemother"},{"key":"2121_CR18","doi-asserted-by":"publisher","unstructured":"Motsch J, Murta de Oliveira C, Stus V, Koksal I, Lyulko O, Boucher HW et al (2020) RESTORE-IMI 1: a multicenter, randomized, double-blind trial comparing efficacy and safety of imipenem\/relebactam vs colistin plus Imipenem in patients with Imipenem-nonsusceptible bacterial infections. Clin Infect Dis 70(9):1799\u20131808. https:\/\/doi.org\/10.1093\/cid\/ciz530","DOI":"10.1093\/cid\/ciz530"},{"issue":"8","key":"2121_CR19","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1001\/jama.2018.0438","volume":"319","author":"KS Kaye","year":"2018","unstructured":"Kaye\u00a0KS, Bhowmick\u00a0T, Metallidis\u00a0S, Bleasdale\u00a0SC, Sagan\u00a0OS, Stus\u00a0V et al (2018) Effect of meropenem-vaborbactam vs piperacillin-tazobactam on clinical cure or improvement and microbial eradication in complicated urinary tract infection: the TANGO I randomized clinical trial. JAMA 319(8):788\u2013799","journal-title":"JAMA"},{"issue":"8","key":"2121_CR20","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.jiac.2017.05.005","volume":"23","author":"C Malaisri","year":"2017","unstructured":"Malaisri\u00a0C, Phuphuakrat\u00a0A, Wibulpolprasert\u00a0A, Santanirand\u00a0P, Kiertiburanakul\u00a0S (2017) A randomized controlled trial of sitafloxacin vs. ertapenem as a\u00a0switch therapy after treatment for acute pyelonephritis caused by extended-spectrum beta-lactamase-producing Escherichia coli: A pilot study. J\u00a0Infect Chemother 23(8):556\u2013562","journal-title":"J Infect Chemother"},{"issue":"8","key":"2121_CR21","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1056\/NEJMoa1801467","volume":"380","author":"FME Wagenlehner","year":"2019","unstructured":"Wagenlehner\u00a0FME, Cloutier\u00a0DJ, Komirenko\u00a0AS, Cebrik\u00a0DS, Krause\u00a0KM, Keepers\u00a0TR et al (2019) Once-daily plazomicin for complicated urinary tract infections. N\u00a0Engl J Med 380(8):729\u2013740","journal-title":"N Engl J Med"}],"container-title":["Die Urologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-023-02121-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00120-023-02121-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-023-02121-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,29]],"date-time":"2023-06-29T08:03:09Z","timestamp":1688025789000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00120-023-02121-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,12]]},"references-count":21,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["2121"],"URL":"https:\/\/doi.org\/10.1007\/s00120-023-02121-5","relation":{},"ISSN":["2731-7064","2731-7072"],"issn-type":[{"value":"2731-7064","type":"print"},{"value":"2731-7072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,12]]},"assertion":[{"value":"12 May 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"F.M.E.\u00a0Wagenlehner deklariert pers\u00f6nliche Geb\u00fchren und andere von Achaogen, pers\u00f6nliche Geb\u00fchren von AstraZeneca, pers\u00f6nliche Geb\u00fchren und andere von Bionorica, andere von Enteris BioPharma, andere von Helperby Therapeutics, pers\u00f6nliche Geb\u00fchren von Janssen, pers\u00f6nliche Geb\u00fchren von MerLion, pers\u00f6nliche Geb\u00fchren von MSD, pers\u00f6nliche Geb\u00fchren und andere von OM Pharma\/Vifor Pharma, pers\u00f6nliche Geb\u00fchren von Pfizer, pers\u00f6nliche Geb\u00fchren von RosenPharma, pers\u00f6nliche Geb\u00fchren und andere von Shionogi, pers\u00f6nliche Geb\u00fchren von VenatoRx, pers\u00f6nliche Geb\u00fchren von GSK, andere vom Deutschen Zentrum f\u00fcr Infektionsforschung (DZIF; Standort Giessen-Marburg-Langen), andere von der Deutschen Forschungsgesellschaft (DFG).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}